Stage (next event)
Phase 2 Initiation
Catalyst Info & Data Links
TITLE: EDP-938 in Respiratory Syncytial Virus (RSV) - Phase 2
WHAT IS THE CATALYST EVENT?
Initiate two Phase 2 RSV studies in pediatric and transplant patients 4Q 2020
Data from RSVP Phase 2b adult outpatient study 3Q 2021
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
December 31, 2020 (Est)
06-14-2020 Enanta Pharmaceuticals Announces Topline Results Showing Edp-938 Achieved Its Primary And Secondary Endpoints In Its Phase 2a Human Challenge Study In Healthy Adults Infected With Respiratory Syncytial Virus (Rsv)
Mechanism of Action
MECHANISM OF ACTION
EDP-938, Enanta’s lead N-protein inhibitor, is being developed for the treatment of RSV infection. Enanta believes EDP-938 is differentiated from fusion inhibitors currently in development by others for RSV because this N-protein inhibitor targets the virus’ replication machinery and has demonstrated high barriers to resistance against the virus in vitro. EDP-938 has also been shown to reduce viral load below the level of detection in vivo. Additionally, it is possible that N-protein inhibitors may be effective treatments at later stages of infection.
Updated by JM
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See what the community is saying - click to see full post